Changing from a Dipeptidyl Peptidase (DPP)-4 Inhibitor to Oral Semaglutide in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Observational Study

抄録

Aims: The aim of the present study was to evaluate the effect of changing from a dipeptidyl peptidase (DPP)-4 inhibitor to oral semaglutide on glycemic control, as reflected by hemoglobin A1c (HbA1c), occasional plasma glucose (PG) and glycoalbumin (GA), and body weight (BW) in routine clinical practice.

Patients and Methods: A search of electronic medical records was performed for patients treated with a DPP4 inhibitor for diabetes mellitus and who were then changed to oral semaglutide because of relatively poor glycemic control from December 2021 to March 2022. A total of 19 patients met these inclusion criteria. Data for these patients were evaluated until the end of August 2022.

Results: HbA1c and occasional PG were significantly decreased compared to baseline (the time of changing treatment) at 4 months and at the final visit (a mean of about 6 months). GA was significantly decreased from baseline at 1 month, 4 months, and at the final visit. BW was also significantly decreased from baseline at 4 months and the final visit. There were no statistically significant changes in low-density lipoprotein cholesterol (LDL-C), triglyceride (TG) or estimated glomerular filtration rate (eGFR).

Conclusion: These results of the present study show that changing from a DPP4 inhibitor to oral semaglutide significantly improved glycemic control, as reflected by HbA1c, occasional PG and GA, and led to a significant reduction in BW after an observational period of over 4 months.